Palatin Technologies

PTN

시가총액 US$1072만

Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript

Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist Phase 1 SAD/MAD study targeted to initiate in the first half of calendar 2027, with initial data targeted in the second half of 2027 Oral MC4R selective agonist Phase 1 SAD/MAD study targeted to initiate in the second half of calendar 2027, with initial data targeted in the first half of 2028 Multiple lipidated and non-lipidated peptide compounds demonstrated potent MC4R agonist activity but are not agonists at melanocortin 1 receptor (MC1R), supporting the potential to minimize or eliminate MC1R-mediated hyperpigmentation Fiscal 2026 collaboration and license revenue totaled $13.2 million, with approximately $9.4 million related to Boehringer Ingelheim and $3.8 million of non-cash license revenue under the Altanispac Labs agreement Cash and cash equivalents were $7.5 million as of June 30, 2026; additional funding will be required to continue advancing development programs and fund operations Conference call and webcast scheduled for September 28, 2026, at 11:00 a.m. ET PRINCETON, N.J.

Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales.

PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.

Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript

Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026 Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027 Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and support safe and effective long-term use Conference call and webcast scheduled for May 13, 2026, at 11:00 a.m. ET PRINCETON, N.J.

Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript

Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndrome Oral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned for once-weekly subcutaneous dosing, with IND submission and clinical trial initiation planned for the second half of 2026 Executed sublicensing of MC1R agonist PL9643 in January 2026, sharpening focus on core obesity portfolio while preserving upside Received $3.8 million in upfront consideration Eligible for future milestone payments and royalties Strengthened balance sheet through successful public financing Completed an $18.2 million public offering, including the full exercise of the over-allotment option, on November 12, 2025 Restored NYSE American listing compliance and trading, re-establishing market visibility and liquidity Teleconference and webcast to be held on February 17, 2026 at 11:00 AM ET PRINCETON, N.J., Feb. 17, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal second quarter ended December 31, 2025, and provided a corporate update.

Palatin Technologies, Inc. (OTC:PTN) Q1 2026 Earnings Call November 13, 2025 11:00 AM EST Company Participants Carl Spana - Co-Founder, President, CEO & Director Steve Wills - CFO, COO, Executive VP, Treasurer & Secretary Conference Call Participants Scott Henry - Alliance Global Partners, Research Division Presentation Operator Greetings. Welcome to Palatin's First Quarter Fiscal Year 2026 Operating Results Conference Call.

Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesity PL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned for once-weekly subcutaneous dosing; IND submission and clinical trial initiation planned for mid-2026 Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for the treatment of retinal diseases in August 2025 Received €2.0M ($2.3M) upfront Achieved €5.5M ($6.5M) research milestone in September 2025 $18.2 million public offering, including full exercise of the over-allotment option, closed on November 12, 2025 Regained compliance with NYSE American listing standards – common stock resumed trading under the symbol "PTN" on November 12, 2025 Teleconference and Webcast to be held on Thursday, November 13, 2025, at 11:00 AM EST PRINCETON, N.J. , Nov. 13, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal first quarter ended September 30, 2025 and provided a corporate update.